Pharmaceutical Sector

Planned Parenthood in trouble

Planned Parenthood in trouble

After videos came out in which Planned Parenthood officials are seen negotiating for provision of fetal tissue from abortions, Republicans in Congress asked to end funding for the organization. Not only this, Planned Parenthood has started losing its clients, as many formerly uninsured women once dependent on the organization have received coverage under the Affordable Care Act.

Now when these women have received coverage under the ACT, they are less reliant on the organization for services like low-cost access to birth control, abortions and other checkups. In many states, the organization is losing its clients.

Roche drug ACE910 wins FDA fast-track designation

Roche drug ACE910 wins FDA fast-track designation

Roche, a pharmaceutical giant, made an announcement on Friday that the US Food and Drug Administration has awarded a designation of breakthrough therapy to Roche for its experimental medicine for hemophilia.

Global Product development head at Genetech said, "People with hemophilia A may require regular and frequent infusions of replacement clotting factor to reduce the risk of unsafe bleeding, and they can develop inhibitors that make replacement ineffective".

AstraZeneca’s new 60 mg dose of Brilinta to hit market this month-end

AstraZeneca’s new 60 mg dose of Brilinta to hit market this month-end

The US Food and Drug Administration (FDA) has given permission to pharmaceutical company AstraZeneca to provide long-term use of its blood thinner Brilinta in patients having a history of heart attacks.

The new dose approved by the FDA is of 60 mg, which can now be used by patients beyond the first year to prevent blood clots that can cause heart attacks, strokes and deaths. The approval is expected to double the number of patients taking the medicine and also to strengthen the company's chances of making revenue. The company expects that Brilinta's sales could reach $3.5 billion by 2023.

Understanding mechanism of FSD drug

Understanding mechanism of FSD drug

After Sprout Pharmaceuticals and Valeant Pharmaceuticals’ female sexual dysfunction (FSD) drug Addyi was given green signal, experts came up with different opinions on the drug. It seems that mechanism of the drug, also called “female Viagra”, is not understood properly.

Last month, female sexual dysfunction (FSD) drug, Addyi from Sprout Pharmaceuticals was approved by the US Food and Drug Administration. When it comes to mechanism of the drug, many misunderstandings are there among people.

Viagra is used for stimulation of a physiological reaction in men, whenever it is required. Addyi is a psychological therapy that promotes desire for women.

Valeant All Set to Buy Manufacturing Rights of AstraZeneca’s Psoriasis Drug

Valeant All Set to Buy Manufacturing Rights of AstraZeneca’s Psoriasis Drug

Three months after Amgen Inc back-tracked, Canada's Valeant Pharmaceuticals International Inc has decided to buy AstraZeneca Plc's psoriasis drug brodalumab.

The previous deal for the drug was called off by Amgen in view of reports showing suicidal tendencies seen in patients who took the drug. On Tuesday, Valeant announced that it will pay $100 million to AstraZeneca for the deal.

In addition, the company will make payments of up to $170 million and $175 million in milestone payments. The company will make the final requests before the drug regulatory authority of the US, for sale, in the last quarter this year.

The drug, however, will not be allowed to enter the markets in specific countries including Japan and a few in Asia in view of regulatory restrictions.

FluGen to get $12 Million in financing

FluGen to get $12 Million in financing

FluGen, the Madison Company, will get $12 million in financing using which it will be able to start first clinical trials of a new type of influenza vaccine. The FluGen's Redee Flu vaccine is based on the research carried out by UW- Madison scientists Yoshihiro Kawaoka and Gabriele Neumann.

CEO Paul Radspinner shared the information that they are planning to file an application with federal regulators in the first half of 2016 for an Investigational New Drug. If the Food and Drug Administration permits them then they can start the clinical trials within 30 days.

FDA calls companies for trial of testosterone supplements

FDA calls companies for trial of testosterone supplements

According to reports, US Food and Drug Administration (FDA) has called companies that create testosterone products for carrying out a large clinical trial in an attempt to find out the accurate benefits and risks of using the hormone.

Christine Nguyen, MD, of the FDA, and colleagues said in a New England Journal of Medicine perspective that their agency is calling testosterone drug makers for making efforts together on one large controlled trial.

Recently, researchers noted the difference between hormone therapy for males and females. They observed that the Women's Health Initiative gave answers of important questions regarding hormone replacement, together with its risks of breast cancer and heart attack. Experts said that there has not been a comparable trial for males.

Americans support Federal Funds for Free Women’s Health exams: Survey

Americans support Federal Funds for Free Women’s Health exams: Survey

If Republicans continue to criticize Planned Parenthood as a key agenda of 2016 campaigns then it could be a problem for them. It has been said so because a Reuters/Ipsos poll has found that Americans are in support of federal funding provision for free women’s health checkups, screenings and contraceptive services.

The poll has also found that the video released by an anti-abortion group earlier this year showing Planned Parenthood officials negotiating prices for aborted fetal tissue has made people negative towards the organization.

But then also, there is a strong support for federal funds to help Planned Parenthood to provide screenings, pregnancy tests and prenatal services to women. Experts said that Republican candidates should now careful choose this topic for discussion.

Novavax Vaccine to Be First To Prevent Common Respiratory Viral Infection

Novavax Vaccine to Be First To Prevent Common Respiratory Viral Infection

The mid-stage study of NovavaxInc’s vaccine which it claim can prevent a common respiratory viral infection is all set to be the first vaccine for the virus that affects almost all American children.

The vaccine for respiratory syncytial virus (RSV) has long eluded developers as deficits in the understanding of the virus' molecular structure and multiple trial failures have come in the way.

As per the estimates given by Wedbush analyst Heather Behanna, RSV vaccine represents a $1 billion opportunity in the United States and potentially doubles worldwide.

AstraZeneca Signs $727.5 Million Deal with Inovio Pharmaceuticals

AstraZeneca Signs $727.5 Million Deal with Inovio Pharmaceuticals

AstraZeneca, a British-Swedish multinational pharmaceutical, recently signed a deal with Inovio Pharmaceuticals worth $727.5 million. The duo has joined hands to develop an experimental drug that could help prevent human papillomavirus (HPV).

As per a Bloomberg report, AstraZeneca will pay Inovio $27.5 million up front and another $700 million if its medicine reaches certain development and commercial milestones.

The drugs developed are said to be combined with immune oncology products that would help the immune system of the body fight off tumors.

It is not the first such move that AstraZeneca has made recently, as last week the company announced that it was partnering with Heptares Therapeutics and Mirati Therapeutics.

AstraZeneca, Inovio join hands to produce cancer fighting drug

AstraZeneca, Inovio join hands to produce cancer fighting drug

Bagging another cancer drug deal, AstraZeneca has entered into an agreement with Inovio Pharmaceuticals. The joint venture will produce a drug for boosting the immune system.

AstraZeneca entered into a third such deal within a week. As per the agreement, AstraZeneca will pay Inovio $27.5 million for now. The latter is also eying a future payment of up to $700 million in the deal.

Sources said that the future payments will depend upon the results seen in the first experiment titled INO-3112 immunotherapy. INO-3112 immunotherapy will be particularly significant in handling cancers caused by human papillomavirus (HPV) types 16 and 18-responsible for cervical cancers.

Earlier, AstraZeneca tied up with Heptares and Mirati.

Sanofi Teams Up With Evotec and Apeiron to Develop New Immune System-Boosting Cancer Medicine

Sanofi Teams Up With Evotec and Apeiron to Develop New Immune System-Boosting

French multinational pharmaceutical company Sanofi said that it is joining hand with Germany’s Evotec and Austrian biotech firm Apeiron Biologics to develop a new immune system-boosting cancer medicine.

The Paris-based company said on Monday that the tie-up would strictly focus its attention on developing small molecule-based immune-oncology treatments that could be given to fight both blood cancer and solid tumors.

The collaboration includes major research and development efforts to advance a first-in-class small molecule approach to treat solid and haematopoietic cancers by enhancing the anti-tumor activity of human lymphocytes.

Eli Lilly Clears First Trial over Cymbalta’s Serious Withdrawal Symptoms

Eli Lilly Clears First Trial over Cymbalta’s Serious Withdrawal Symptoms

American global pharmaceutical company Eli Lilly on Friday cleared the first trial involving claims that its antidepressant Cymbalta caused severe withdrawal symptoms, including suicidal thoughts and electric shock-like sensations.

It has been said that the Indianapolis based pharmaceutical company was sued roughly by 250 plaintiffs who claimed that the company downplayed warnings about symptoms that occur after a patient quits the drug.

The trial about Cymbalta, which has annual sales of about $3.9 billion, is the first of four trials scheduled for this month.The lawsuit was filed by Claudia Herrera in federal court in California,

Gilead Sciences’ shares up 300% in three years

Gilead Sciences’ shares up 300% in three years

Gilead Sciences Inc.'s shares jumped 4.46% in the past week, while the increment turned out to be 2.45% over the past 4 weeks.

Over the past week, the company witnessed an overwhelming performance in the share market with increase in the S&P 500 by 3.26%. In the past quarter, the company's shares rose 12.64%.

The elevation in the share value of past 52 weeks turns out to be 27.86% for Gilead Sciences. As on June 24 this year, Gilead's shares recorded one year high of $123.37. It saw a one year low at $85.95 on December 23, last year.

Now, a number of market analysts are sending in suggestions for the company for further course of action. In fact, as many as five analysts have rated Gilead as a potential unit for investment.

Allergan to buy Naurex for $560 Million

Allergan to buy Naurex for $560 Million

On Sunday, Allergan publicized that it is buying Naurex, a drug manufacturing company. Allergan will purchase the company by spending $560 million in cash. Discussions with regard to the deal started late last year.

Dublin-based pharmaceutical giant, Allergan PLC, has announced that it is going to purchase Naurex for $560 million in cash. Talks on acquisition started late last year.

The announcement has come at a time when Allergan is in talks to sell its generic drug division to Israel-based Teva Pharmaceutical Industries Ltd. It is said the deal worth around $45 billion could be announced by Monday.

Teva is known for its production of generic drugs and Allergan, which was earlier known as Actavis, is known for Botox treatment.

Gilead Sciences COO sells 100,000 Shares

Gilead Sciences COO sells 100,000 Shares

In a legal filing with the Securities & Exchange Commission on July 9, Gilead Sciences has disclosed insider sales by its chief operating officer, John F Milligan on Tuesday, July 7. Milligan sold 100,000 shares of Gilead Sciences stock in a transaction totaling to $11,444,000.

Following the transaction, Milligan now directly owns 1,029,108 shares of the company's stock, valued at approximately $117,771,119.52. The present trading seems to be in continuation of the past six months transactions which have caused a change of -20.53% in the total insider ownership.

At Gilead Sciences, a 52 week low of $84.75 and a 52 week high of $123.37 has been recorded. The company has a market cap of $167.15 billion and a price-to-earnings ratio of 12.97.

Gilead Sciences declines to $115.13 per Share

Gilead Sciences declines to $115.13 per Share

Gilead Sciences stock declined in the last trading session to $115.1. The stock has been recently under pressure as investors feel that the company has been overvalued. Many other pharmaceutical companies are working hard on developing a treatment for hepatitis C.

After the recommencement of the session, the company's stock reached the higher end at $116.42 while it hit a low of $113.1.

With a total volume of 10,182,959 shares, the last trade was called at $115.13. The company has a 52-week high of $123.37.

The company has a market cap of $169,196 million and there are 1,469,606,000 shares in outstanding. The 52-week low of the share price is $84.75.

Major health insurers under pressure to yield deals after Aetna’s Humana deal

Major health insurers under pressure to yield deals after Aetna’s Humana deal

After Aetna Inc. and Humana Inc. merged, other major health insurers have also come under pressure to sign such deals. According to reports, next deal could be between Cigna Corp. and Anthem Inc. These insurers were said to be interested in buying Humana.

However, Humana was acquired by Aetna on Friday. According to Ana Gupte, an analyst at Leerink Partners in New York, “It paves the way for Cigna and Anthem. Cigna has fewer choices at this point”.

Aetna acquired Humana in a $35 billion cash-and-stock deal. It is the first such deal among the largest companies in the industry. Now, major health insurers are concerned regarding expanding more following the US reform known as Obamacare. The act led to a competition for new customers and cut margins.

Vertex Pharmaceuticals wins US Approval for Orkambi to treat cystic fibrosis

Vertex Pharmaceuticals wins US Approval for Orkambi to treat cystic fibrosis

Vertex Pharmaceuticals has received green signal from the FDA for its combination drug Orkambi for the treatment of most common form of cystic fibrosis. As per the analysts, the approval will prove extremely beneficial for the company.

If the circumstances are considered of May then it was not sure that that Vertex Pharmaceuticals' combination therapy for the most common form of cystic fibrosis will get approval. But after few days, the drug Orkambi got approved.

The drug has been made by combining Kalydeco with lumacaftor. It is expected that the FDA will widen its approval area for the drug for patients having cystic fibrosis and are six years or older. By expanding the approval, more number of people will be benefitted.

Anthem $47 billion proposes to acquire Cigna rejected

Anthem $47 billion proposes to acquire Cigna rejected

A proposal offered by Anthem on Saturday to buy Cigna Corp for $47 billion was rejected by smaller health insurer.

Cigna said Anthem’s non-binding proposal was inadequate and not in the best interests of shareholders. The proposal is for $184 a share, about 31% of which would be paid in Anthem shares and the rest in cash.

That’s a 29% premium to Cigna’s average closing price in the past 20 trading sessions. Anthem said Saturday that the total transaction value is $53.8 billion, including net debt.

On Sunday, Cigna said its rival was facing a number of major issues. After citing a data breach Anthem in February the company mentioned about Anthem’s lack of a growth strategy, its membership in the Blue Cross Blue Shield Association and related antitrust actions.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate


Syndicate content